Upstream Bio (UPB) Cash & Equivalents (2023 - 2026)

Upstream Bio's Cash & Equivalents history runs 4 years deep, the most recent figure standing at $96.7 million for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 35.63% year-over-year to $96.7 million in Q1 2026; TTM through Mar 2026 was $96.7 million, a 35.63% increase from a year earlier, with the FY2025 full-year figure at $101.6 million, down 68.83% from the prior year.
• Cash & Equivalents slipped to $96.7 million in Q1 2026 per UPB's latest filing, from $101.6 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $325.9 million in Q4 2024 and bottomed at $25.8 million in Q4 2023.
• The 4-year median for Cash & Equivalents is $47.3 million (2024), against an average of $81.6 million.
• Across the five-year window, Cash & Equivalents surged 1161.53% in 2024 and tumbled 68.83% in 2025, its largest moves.
• Year by year, Cash & Equivalents stood at $25.8 million in 2023, then jumped by 1161.53% to $325.9 million in 2024, then tumbled by 68.83% to $101.6 million in 2025, then retreated by 4.78% to $96.7 million in 2026.
• Per Business Quant, the three latest UPB Cash & Equivalents figures stand at $96.7 million (Q1 2026), $101.6 million (Q4 2025), and $72.2 million (Q3 2025).